1. Cell Biology

C/EBPδ-induced epigenetic changes control the dynamic gene transcription of S100a8 and S100a9

  1. Saskia-Larissa Jauch-Speer
  2. Marisol Herrera-Rivero
  3. Nadine Ludwig
  4. Bruna Caroline Véras De Carvalho
  5. Leonie Martens
  6. Jonas Wolf
  7. Achmet Imam Chasan
  8. Anika Witten
  9. Birgit Markus
  10. Bernhard Schieffer
  11. Thomas Vogl
  12. Jan Rossaint
  13. Monika Stoll
  14. Johannes Roth  Is a corresponding author
  15. Olesja Fehler
  1. University of Münster, Germany
  2. University Hospital Münster, Germany
  3. University Hospital Marburg, Germany
https://doi.org/10.7554/eLife.75594
Share this article
Cite this article
  1. Saskia-Larissa Jauch-Speer
  2. Marisol Herrera-Rivero
  3. Nadine Ludwig
  4. Bruna Caroline Véras De Carvalho
  5. Leonie Martens
  6. Jonas Wolf
  7. Achmet Imam Chasan
  8. Anika Witten
  9. Birgit Markus
  10. Bernhard Schieffer
  11. Thomas Vogl
  12. Jan Rossaint
  13. Monika Stoll
  14. Johannes Roth
  15. Olesja Fehler
(2022)
C/EBPδ-induced epigenetic changes control the dynamic gene transcription of S100a8 and S100a9
eLife 11:e75594.
https://doi.org/10.7554/eLife.75594
  2. Download BibTeX
  3. Download .RIS

Abstract

The proinflammatory alarmins S100A8 and S100A9 are among the most abundant proteins in neutrophils and monocytes but are completely silenced after differentiation to macrophages. The molecular mechanisms of the extraordinarily dynamic transcriptional regulation of S100a8 and S100a9 genes, however, are only barely understood. Using an unbiased genome-wide CRISPR/Cas9 knockout based screening approach in immortalized murine monocytes we identified the transcription factor C/EBPδ as a central regulator of S100a8 and S100a9 expression. We showed that S100A8/A9 expression and thereby neutrophil recruitment and cytokine release were decreased in C/EBPδ KO mice in a mouse model of acute lung inflammation. S100a8 and S100a9 expression was further controlled by the C/EBPδ-antagonists ATF3 and FBXW7. We confirmed the clinical relevance of this regulatory network in subpopulations of human monocytes in a clinical cohort of cardiovascular patients. Moreover, we identified specific C/EBPδ-binding sites within S100a8 and S100a9 promoter regions, and demonstrated that C/EBPδ-dependent JMJD3-mediated demethylation of H3K27me3 is indispensable for their expression. Overall, our work uncovered C/EBPδ as a novel regulator of S100a8 and S100a9 expression. Therefore, C/EBPδ represents a promising target for modulation of inflammatory conditions that are characterised by S100a8 and S100a9 overexpression.

Data availability

data and code availabilityhttps://www.ncbi.nlm.nih.gov/bioproject/PRJNA754262https://www.ncbi.nlm.nih.gov/bioproject/PRJNA706411https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE200730

The following data sets were generated

Article and author information

Author details

  1. Saskia-Larissa Jauch-Speer

    Institute of Immunology, University of Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.

  2. Marisol Herrera-Rivero

    Department of Genetic Epidemiology, University of Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7064-9487

  3. Nadine Ludwig

    Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.

  4. Bruna Caroline Véras De Carvalho

    Institute of Immunology, University of Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.

  5. Leonie Martens

    Institute of Immunology, University of Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.

  6. Jonas Wolf

    Institute of Immunology, University of Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.

  7. Achmet Imam Chasan

    Institute of Immunology, University of Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5137-6890

  8. Anika Witten

    Department of Genetic Epidemiology, University of Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.

  9. Birgit Markus

    Clinic for Cardiology, Angiology and Internal Intensive Medicine, University Hospital Marburg, Marburg, Germany
    Competing interests
    The authors declare that no competing interests exist.

  10. Bernhard Schieffer

    Clinic for Cardiology, Angiology and Internal Intensive Medicine, University Hospital Marburg, Marburg, Germany
    Competing interests
    The authors declare that no competing interests exist.

  11. Thomas Vogl

    Institute of Immunology, University of Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.

  12. Jan Rossaint

    Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.

  13. Monika Stoll

    Department of Genetic Epidemiology, University of Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.

  14. Johannes Roth

    Institute of Immunology, University of Münster, Münster, Germany
    For correspondence
    rothj@uni-muenster.de
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7035-8348

  15. Olesja Fehler

    Institute of Immunology, University of Münster, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6386-7080

Funding

Deutsche Forschungsgemeinschaft (CRC 1009 B9)

  • Johannes Roth

Deutsche Forschungsgemeinschaft (CRC 1009 Z2)

  • Johannes Roth

Deutsche Forschungsgemeinschaft (CRC 1009 B8)

  • Thomas Vogl

Deutsche Forschungsgemeinschaft (CRU 342 P3)

  • Johannes Roth

Deutsche Forschungsgemeinschaft (RO 1190/14-1)

  • Johannes Roth

Deutsche Forschungsgemeinschaft (CRU 342 P5)

  • Thomas Vogl

Interdisciplinary Center of Clinical Research at the University of Münster (Ro2/023/19)

  • Johannes Roth

Interdisciplinary Center of Clinical Research at the University of Münster (Vo2/011/19)

  • Thomas Vogl

EU EFRE Bio NRW programme (005-1007-0006)

  • Monika Stoll

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Mouse experiments were in accordance with German Animal Welfare Legislation and performed as approved by the North Rhine-Westphalia Office of Nature, Environment and Consumer Protection (LANUV) and the District Government and District Veterinary Office Muenster under the reference number 81-02.04.2019.A445.

Human subjects: The BioNRW Study is conducted in accordance with the guidelines of the Declaration of Helsinki. The research protocol, including the case report forms, was approved by the local ethics committee (#245-12). Written informed consent was obtained from all study participants.

Copyright

© 2022, Jauch-Speer et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,454
    views
  • 278
    downloads
  • 12
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Saskia-Larissa Jauch-Speer
  2. Marisol Herrera-Rivero
  3. Nadine Ludwig
  4. Bruna Caroline Véras De Carvalho
  5. Leonie Martens
  6. Jonas Wolf
  7. Achmet Imam Chasan
  8. Anika Witten
  9. Birgit Markus
  10. Bernhard Schieffer
  11. Thomas Vogl
  12. Jan Rossaint
  13. Monika Stoll
  14. Johannes Roth
  15. Olesja Fehler
(2022)
C/EBPδ-induced epigenetic changes control the dynamic gene transcription of S100a8 and S100a9
eLife 11:e75594.
https://doi.org/10.7554/eLife.75594

Share this article

https://doi.org/10.7554/eLife.75594

Categories and tags

Research organism

Further reading

    1. Cell Biology

    Oversized cells activate global proteasome-mediated protein degradation to maintain cell size homeostasis

    Shixuan Liu, Ceryl Tan ... Ran Kafri
    Research Advance

    Proliferating animal cells maintain a stable size distribution over generations despite fluctuations in cell growth and division size. Previously, we showed that cell size control involves both cell size checkpoints, which delay cell cycle progression in small cells, and size-dependent regulation of mass accumulation rates (Ginzberg et al., 2018). While we previously identified the p38 MAPK pathway as a key regulator of the mammalian cell size checkpoint (S. Liu et al., 2018), the mechanism of size-dependent growth rate regulation has remained elusive. Here, we quantified global rates of protein synthesis and degradation in cells of varying sizes, both under unperturbed conditions and in response to perturbations that trigger size-dependent compensatory growth slowdown. We found that protein synthesis rates scale proportionally with cell size across cell cycle stages and experimental conditions. In contrast, oversized cells that undergo compensatory growth slowdown exhibit a superlinear increase in proteasome-mediated protein degradation, with accelerated protein turnover per unit mass, suggesting activation of the proteasomal degradation pathway. Both nascent and long-lived proteins contribute to the elevated protein degradation during compensatory growth slowdown, with long-lived proteins playing a crucial role at the G1/S transition. Notably, large G1/S cells exhibit particularly high efficiency in protein degradation, surpassing that of similarly sized or larger cells in S and G2, coinciding with the timing of the most stringent size control in animal cells. These results collectively suggest that oversized cells reduce their growth efficiency by activating global proteasome-mediated protein degradation to promote cell size homeostasis.

    1. Cell Biology
    2. Physics of Living Systems

    A high-throughput platform for single-molecule tracking identifies drug interaction and cellular mechanisms

    David Trombley McSwiggen, Helen Liu ... Hilary P Beck
    Research Article

    The regulation of cell physiology depends largely upon interactions of functionally distinct proteins and cellular components. These interactions may be transient or long-lived, but often affect protein motion. Measurement of protein dynamics within a cellular environment, particularly while perturbing protein function with small molecules, may enable dissection of key interactions and facilitate drug discovery; however, current approaches are limited by throughput with respect to data acquisition and analysis. As a result, studies using super-resolution imaging are typically drawing conclusions from tens of cells and a few experimental conditions tested. We addressed these limitations by developing a high-throughput single-molecule tracking (htSMT) platform for pharmacologic dissection of protein dynamics in living cells at an unprecedented scale (capable of imaging >106 cells/day and screening >104 compounds). We applied htSMT to measure the cellular dynamics of fluorescently tagged estrogen receptor (ER) and screened a diverse library to identify small molecules that perturbed ER function in real time. With this one experimental modality, we determined the potency, pathway selectivity, target engagement, and mechanism of action for identified hits. Kinetic htSMT experiments were capable of distinguishing between on-target and on-pathway modulators of ER signaling. Integrated pathway analysis recapitulated the network of known ER interaction partners and suggested potentially novel, kinase-mediated regulatory mechanisms. The sensitivity of htSMT revealed a new correlation between ER dynamics and the ability of ER antagonists to suppress cancer cell growth. Therefore, measuring protein motion at scale is a powerful method to investigate dynamic interactions among proteins and may facilitate the identification and characterization of novel therapeutics.

    1. Cell Biology

    Atlas of Fshr expression from novel reporter mice

    Hongqian Chen, Hui-Qing Fang ... Peng Liu
    Tools and Resources

    The FSH-FSHR pathway has been considered an essential regulator in reproductive development and fertility. But there has been emerging evidence of FSHR expression in extragonadal organs. This poses new questions and long-term debates regarding the physiological role of the FSH-FSHR, and underscores the need for reliable, in vivo analysis of FSHR expression in animal models. However, conventional methods have proven insufficient for examining FSHR expression due to several limitations. To address this challenge, we developed Fshr-ZsGreen reporter mice under the control of Fshr endogenous promoter using CRISPR-Cas9. With this novel genetic tool, we provide a reliable readout of Fshr expression at single-cell resolution level in vivo and in real time. Reporter animals were also subjected to additional analyses,to define the accurate expression profile of FSHR in gonadal and extragonadal organs/tissues. Our compelling results not only demonstrated Fshr expression in intragonadal tissues but also, strikingly, unveiled notably increased expression in Leydig cells, osteoblast lineage cells, endothelial cells in vascular structures, and epithelial cells in bronchi of the lung and renal tubes. The genetic decoding of the widespread pattern of Fshr expression highlights its physiological relevance beyond reproduction and fertility, and opens new avenues for therapeutic options for age-related disorders of the bones, lungs, kidneys, and hearts, among other tissues. Exploiting the power of the Fshr knockin reporter animals, this report provides the first comprehensive genetic record of the spatial distribution of FSHR expression, correcting a long-term misconception about Fshr expression and offering prospects for extensive exploration of FSH-FSHR biology.